Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
According to industrial sources, chemical giant E. I. Du Pont de Nemours and Company ( DD - Analyst Report ) has launched the sale process of its car paints business, which could bring in more than $4 billion.
The sources further reported that the sale will pull the interests of the private equity players. The private parties believe that they can cut costs easily so that the unit can reap more profits. Other chemical companies may also be interested in the sale, as per the reports.
DuPont's adviser on the deal, Credit Suisse Group ( CS - Snapshot Report ) , sent financial documents/details to potentially interested parties related to the sale.
DuPont’s Coatings business reported sales of $1.1 billion in the fourth quarter of 2011. Despite soft demand for consumer electronics segment and weak markets for housing and construction, DuPont delivered exceptional results for full-year 2011.
The company reported earnings of 35 cents per share in the fourth quarter of 2011 compared with 50 cents in the year-ago quarter. The profit exceeded the Zacks Consensus Estimate of 33 cents per share.
A higher tax rate in the quarter led to the year-over-year decline in profit. Further, higher selling prices during the quarter was offset by increased spending on selling, marketing and research and development, higher costs for raw materials, energy and freight as well as lower sales volumes.
For full-year 2011, the company reported earnings of $3.93 per share, up 20% from $3.28 per share in 2010, exceeding the Zacks Consensus Estimate by a penny.
Sales in the quarter grew 14% to $8.4 billion due to 14% increase in prices and higher agriculture segment sales. However, the quarter witnessed declining sales volumes due to destocking in photovoltaics, polymer and industrial supply chains. The consumer electronics and construction division also faced soft demand. For fiscal year 2011, sales jumped by 20% to $38.0 billion.
We believe that the slowdown in global economic growth in the fourth quarter will continue in the first quarter of 2012, gradually improving in the second half of 2012. The company also faces stiff competition from The Dow Chemical Company ( DOW - Analyst Report ) and BASF SE ( BASFY ) .
However, markets for DuPont's agriculture and food businesses continue to be strong, especially with a strong planting season in Latin America. Therefore, the company retains a Zacks #3 Rank, which translates into a short-term (1 to 3 months) Hold rating and we have recommended the shares of the company as Neutral for the long-term (more than 6 months).
Read the full Analyst Report on DD
Read the full Snapshot Report on CS
Read the full Analyst Report on DOW
Read the full on BASFY